Polynucleotides encoding anti-amyloid beta monoclonal antibodies
US9585956B2 · kind B2 · utility
6Cited by
115References
21Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 22, 2015 |
| Grant date | Mar 7, 2017 |
| Priority date | — |
| Expiry date | Sep 22, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.